Xencor [XNCR] vs Zymeworks [ZYME] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Xencor Inc. wins in 10 metrics, Zymeworks Inc. wins in 8 metrics, with 0 ties. Xencor Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Xencor Inc. Zymeworks Inc. Better
P/E Ratio (TTM) -10.48 3.79 Zymeworks Inc.
Price-to-Book Ratio 1.47 7.32 Xencor Inc.
Debt-to-Equity Ratio 29.54 6.80 Zymeworks Inc.
PEG Ratio 0.12 0.05 Zymeworks Inc.
EV/EBITDA -3.55 -20.40 Xencor Inc.
Profit Margin (TTM) -73.20% -76.56% Xencor Inc.
Operating Margin (TTM) -189.92% -1,755.55% Xencor Inc.
Return on Equity -14.07% -26.72% Xencor Inc.
Return on Assets (TTM) -12.14% -14.29% Xencor Inc.
Free Cash Flow (TTM) $-138.27M $-35.36M Zymeworks Inc.
1-Year Return 48.50% 119.86% Zymeworks Inc.
Price-to-Sales Ratio (TTM) 7.58 18.46 Xencor Inc.
Enterprise Value $591.95M $1.73B Zymeworks Inc.
EV/Revenue Ratio 4.71 16.33 Xencor Inc.
Revenue per Share (TTM) $2 $1 Xencor Inc.
Earnings per Share (Diluted) $-1.24 $-1.08 Zymeworks Inc.
Beta (Stock Volatility) 0.99 1.20 Xencor Inc.
Short % of Float 19.84% 8.16% Zymeworks Inc.

Xencor Inc. vs Zymeworks Inc. Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Xencor Inc.1.87%-2.56%-14.52%-4.99%-34.03%-23.46%
Zymeworks Inc.1.00%-1.77%-9.07%-0.41%-7.13%-8.53%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Xencor Inc.48.50%-57.10%-67.41%-17.61%53.09%53.09%
Zymeworks Inc.119.86%189.85%-20.78%93.31%93.31%93.31%

Performance & Financial Health Analysis: Xencor Inc. vs Zymeworks Inc.

MetricXNCRZYME
Market Information
Market Cap i$951.94M$1.96B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i670,230626,460
90 Day Avg. Volume i848,407729,503
Last Close$11.42$24.35
52 Week Range$6.92 - $18.69$11.51 - $29.75
% from 52W High-38.90%-18.15%
All-Time High$58.35 (Feb 22, 2021)$59.03 (Jan 11, 2021)
% from All-Time High-80.43%-58.75%
Growth Metrics
Quarterly Revenue Growth-0.47%-0.92%
Quarterly Earnings Growth-0.60%-0.92%
Financial Health
Profit Margin (TTM) i-0.73%-0.77%
Operating Margin (TTM) i-1.90%-17.56%
Return on Equity (TTM) i-0.14%-0.27%
Debt to Equity (MRQ) i29.546.80
Cash & Liquidity
Book Value per Share (MRQ)$8.84$3.60
Cash per Share (MRQ)$7.47$3.10
Operating Cash Flow (TTM) i$-135,116,992$-33,005,000
Levered Free Cash Flow (TTM) i$-39,165,124$-12,959,125
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Xencor Inc. vs Zymeworks Inc.

MetricXNCR (Apr 26, 2026)ZYME (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i-10.483.79
Forward P/E i-4.2733.43
PEG Ratio i0.120.05
Price to Sales (TTM) i7.5818.46
Price to Book (MRQ) i1.477.32
Market Capitalization
Market Capitalization i$951.94M$1.96B
Enterprise Value i$591.95M$1.73B
Enterprise Value Metrics
Enterprise to Revenue i4.7116.33
Enterprise to EBITDA i-3.55-20.40
Risk & Other Metrics
Beta i0.991.20
Book Value per Share (MRQ) i$8.84$3.60

Financial Statements Comparison: Xencor Inc. vs Zymeworks Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricXNCR (2025)ZYME (2025)
Revenue/Sales i125.58M105.97M
Cost of Goods Sold iN/AN/A
COGS % of Revenue i0.0%0.0%
Gross Profit iN/AN/A
Gross Margin i0.0%0.0%
Research & Development i239.43M137.00M
Operating Income (EBIT) i-177.50M-92.54M
Operating Margin i-141.4%-87.3%
EBITDA i-139.54M-80.82M
EBITDA Margin i-111.1%-76.3%
Pre-Tax Income i-89.63M-79.75M
Pre-Tax Income % of Revenue i-71.4%-75.3%
Income Tax i2.50M1.38M
Income Tax % of Revenue i2.0%1.3%
Net Income (Profit) i-92.14M-81.13M
Profit Margin i-73.4%-76.6%

Balance Sheet & Liquidity Metrics

MetricXNCR (2025)ZYME (2025)
Cash & Equivalents i54.07M41.16M
Total Current Assets i599.82M248.77M
Total Current Assets % of Revenue i477.7%234.8%
Total Current Liabilities i95.91M42.32M
Total Current Liabilities % of Revenue i76.4%39.9%
Long-Term Debt i141.22M14.80M
Long-Term Debt % of Revenue i112.5%14.0%
Total Shareholders Equity i635.59M268.50M
Retained Earnings i-795.96M-953.16M
Retained Earnings % of Revenue i-633.8%-899.5%
Property, Plant & Equipment i81.34M29.56M

Cash Flow Statement Comparison

MetricXNCR (2025)ZYME (2025)
Operating Cash Flow i-62.53M-40.00M
Operating Cash Flow % of Revenue i-49.8%-37.7%
Capital Expenditures i-3.15M-1.52M
Free Cash Flow i-138.27M-35.36M
FCF Margin i-110.1%-33.4%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-41.70M

Short Interest & Institutional Ownership Analysis

MetricXNCRZYME
Shares Short i10.31M4.08M
Short Ratio i10.985.42
Short % of Float i19.84%8.16%
Shares Outstanding i71.87M75.19M
Float Shares i53.85M72.80M
% Held by Insiders i1.26%1.26%
% Held by Institutions i119.35%98.45%
% Held by Public i-20.61%0.29%

Dividend Analysis & Yield Comparison: Xencor Inc. vs Zymeworks Inc.

MetricXNCRZYME
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A